1. Home
  2. BOLD vs PCLA Comparison

BOLD vs PCLA Comparison

Compare BOLD & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • PCLA
  • Stock Information
  • Founded
  • BOLD 2018
  • PCLA 2008
  • Country
  • BOLD United States
  • PCLA Japan
  • Employees
  • BOLD N/A
  • PCLA N/A
  • Industry
  • BOLD
  • PCLA Building Products
  • Sector
  • BOLD
  • PCLA Consumer Discretionary
  • Exchange
  • BOLD Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • BOLD 30.3M
  • PCLA 32.3M
  • IPO Year
  • BOLD 2024
  • PCLA 2025
  • Fundamental
  • Price
  • BOLD $1.10
  • PCLA $2.18
  • Analyst Decision
  • BOLD Buy
  • PCLA
  • Analyst Count
  • BOLD 3
  • PCLA 0
  • Target Price
  • BOLD $4.00
  • PCLA N/A
  • AVG Volume (30 Days)
  • BOLD 362.2K
  • PCLA 2.3M
  • Earning Date
  • BOLD 08-11-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • BOLD N/A
  • PCLA N/A
  • EPS Growth
  • BOLD N/A
  • PCLA N/A
  • EPS
  • BOLD N/A
  • PCLA N/A
  • Revenue
  • BOLD N/A
  • PCLA $5,475,228.00
  • Revenue This Year
  • BOLD N/A
  • PCLA N/A
  • Revenue Next Year
  • BOLD N/A
  • PCLA N/A
  • P/E Ratio
  • BOLD N/A
  • PCLA N/A
  • Revenue Growth
  • BOLD N/A
  • PCLA 40.19
  • 52 Week Low
  • BOLD $1.00
  • PCLA $0.37
  • 52 Week High
  • BOLD $4.72
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • PCLA N/A
  • Support Level
  • BOLD N/A
  • PCLA N/A
  • Resistance Level
  • BOLD N/A
  • PCLA N/A
  • Average True Range (ATR)
  • BOLD 0.00
  • PCLA 0.00
  • MACD
  • BOLD 0.00
  • PCLA 0.00
  • Stochastic Oscillator
  • BOLD 0.00
  • PCLA 0.00

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: